Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis. Issue 2 (20th December 2021)

• Record Type: Journal Article
• Authors: Wu, Linyong; Liao, Wei; Wang, Xiaodong; Zhao, Yujia; Pang, Jinshu; Chen, Yuji; Yang, Hong; He, Yun
• Is Part Of: Bioengineered. Volume 12:Issue 2(2021)
• Page Start: 10302
• Page End: 10318
• Publication Date: 2021-12-20
• Subjects: Pan-cancer -- Long non-coding RNA ASB16-AS1 -- Prognosis -- Immune infiltration -- Molecular characteristics; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.1996054
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Long non-coding RNA known as ASB16 antisense RNA1 (ASB16-AS1) has been proven to be an oncogene, and the relationship between ASB16-AS1 and immunity is still under studied. This study aims to explore the expression and prognostic potential of ASB16-AS1, and to visualize the relationship between ASB16-AS1 expression and immune infiltration in pan-cancer analysis. We clarified ASB16-AS1 expression patterns and its relationship with prognosis through multi-platform and multi-database sources. We also verified the function of ASB16-AS1 in liver hepatocellular carcinoma (LIHC). A variety of immune cell content evaluation methods were used to mutually verify the correlation between ASB16-AS1 and immune infiltration. Finally, the relationships between ASB16-AS1 and molecular characteristics were further explored. In terms of comprehensive analysis, compared with non-tumor tissues, ASB16-AS1 was highly expressed in tumor tissues, and indicated the value of poor prognosis in multiple cancer types. Functional assays, such as counting kit-8 assay, transwell assay and scratch-wound assay verified that high ASB16-AS1 expression promoted tumor progression in LIHC. ASB16-AS1 was positively correlated with B cells, T cells CD4+ and T cells CD8+ in most cancer types, and negatively correlated with macrophages, dendritic cells and neutrophils in some cancer types. In addition, there were different interaction modes between ASB16-AS1 and molecular features, such as the relationship with oncogenic signaling pathways, showing that the high ASB16-AS1 expression was related to alterations in oncogenic signaling pathways. Our study emphasizes that ASB16-AS1 is a potential pan-cancer prognostic marker, whichs is associated with the immune infiltration in multiple cancer types.